Browsing Tag
ASX:PAR
1 post
Paradigm Biopharmaceuticals (ASX: PAR) hits key Phase 3 milestone as dosing begins in U.S. and Australia
Paradigm Biopharmaceuticals (ASX: PAR) begins dosing in its pivotal Phase 3 osteoarthritis trial, setting up a mid-2026 data readout that could redefine its future.